H.R. 4117
Referred to CommitteeCompetitive DRUGS Act of 2017
Latest Action
Referred to the Subcommittee on Digital Commerce and Consumer Protection.
10/27/2017 • House
Summary
Competitive Deals Resulting in Unleashed Generics and Savings Act of 2017 or the Competitive DRUGS Act of 2017
This bill establishes a series of requirements and prohibitions regarding certain patent infringement agreements between brand name and generic drug manufacturers in which the generic drug manufacturer agrees to delay the availability of applicable generic drugs. Among other things, the bill specifies that such agreements constitute an unfair method of competition and are subject to specified civil penalties.
Introduced in House • 10/25/2017
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (38)
Party Breakdown
Sponsor
Cosponsors (37)
Bill Journey
Originated in the House
Introduced
October 25, 2017
Referred to the Committee on Ways and Means, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law